Kurs
-6,10%
Kalender
| Est. tid* | ||
| 2027-10-28 | 07:00 | Kvartalsrapport 2027-Q3 |
| 2027-07-26 | 07:00 | Kvartalsrapport 2027-Q2 |
| 2027-04-30 | 07:00 | Kvartalsrapport 2027-Q1 |
| 2027-02-08 | N/A | Bokslutskommuniké 2026 |
| 2026-11-03 | 07:00 | Kvartalsrapport 2026-Q3 |
| 2026-07-28 | 07:00 | Kvartalsrapport 2026-Q2 |
| 2026-05-12 | N/A | X-dag ordinarie utdelning PHIA 0.85 EUR |
| 2026-05-08 | N/A | Årsstämma |
| 2026-05-06 | 07:00 | Kvartalsrapport 2026-Q1 |
| 2026-02-10 | - | Bokslutskommuniké 2025 |
| 2025-11-04 | - | Kvartalsrapport 2025-Q3 |
| 2025-07-29 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-12 | - | X-dag ordinarie utdelning PHIA 0.85 EUR |
| 2025-05-08 | - | Årsstämma |
| 2025-05-06 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-19 | - | Bokslutskommuniké 2024 |
| 2024-10-28 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-29 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-07 | - | Årsstämma |
| 2024-04-29 | - | Kvartalsrapport 2024-Q1 |
| 2024-01-29 | - | Bokslutskommuniké 2023 |
| 2023-10-23 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-11 | - | X-dag ordinarie utdelning PHIA 0.85 EUR |
| 2023-05-09 | - | Årsstämma |
| 2023-04-24 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-21 | - | Bokslutskommuniké 2022 |
| 2022-10-24 | - | Kvartalsrapport 2022-Q3 |
| 2022-09-30 | - | Extra Bolagsstämma |
| 2022-07-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | X-dag ordinarie utdelning PHIA 0.85 EUR |
| 2022-05-10 | - | Årsstämma |
| 2022-04-25 | - | Kvartalsrapport 2022-Q1 |
| 2022-01-24 | - | Bokslutskommuniké 2021 |
| 2021-10-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-10 | - | X-dag ordinarie utdelning PHIA 0.85 EUR |
| 2021-05-06 | - | Årsstämma |
| 2021-04-26 | - | Kvartalsrapport 2021-Q1 |
| 2021-01-25 | - | Bokslutskommuniké 2020 |
| 2020-10-19 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-26 | - | Extra Bolagsstämma |
| 2020-05-05 | - | X-dag ordinarie utdelning PHIA 0.85 EUR |
| 2020-04-30 | - | Årsstämma |
| 2020-04-20 | - | Kvartalsrapport 2020-Q1 |
| 2020-01-28 | - | Bokslutskommuniké 2019 |
| 2019-10-28 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-29 | - | Kvartalsrapport 2019-Q1 |
Beskrivning
| Land | Nederländerna |
|---|---|
| Sektor | Handel & varor |
| Industri | Sällanköpsvaror |
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
December 4, 2025
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today reaffirmed that its 2026 outlook will be issued as planned on February 10, in line with the company’s previously communicated schedule.
As previously guided, the company expects continued performance improvement with sequential comparable sales growth, expanded margins (despite tariff headwinds) and strong cashflow. The company continues to expect comparative sales growth to accelerate sequentially in 2026 towards mid-single-digit growth in line with the current trajectory and supported by continued solid order momentum. This is in line with performance in the last four consecutive quarters.
The company has not released any early view of its forthcoming guidance. Yesterday at an industry conference, in answer to a question, the company confirmed that sequential acceleration towards mid-single-digit growth continues to be its expectation and noted this does not imply doubling growth every single year in the company’s multi-year trajectory.
Philips will share its outlook as part of its planned disclosure on February 10.
For further information, please contact:
Steve Heywood
Philips Global External Relations
Tel.: +31 638 363 589
E-mail: steve.heywood@philips.com
Dorin Danu
Philips Investor Relations
Tel.: +31 205 977 055
E-Mail: dorin.danu@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.